• p.Met41Val genotype and transfusion dependence are risks for decreased survival in VEXAS syndrome; ear chondritis confers better prognosis.

  • Differences in disease severity of VEXAS syndrome are linked with residual translation of the cytoplasmic isoform of UBA1 (UBA1b).

Somatic mutations in UBA1 cause vacuoles, E1 ubiquitin-activating enzyme, X-linked, autoinflammatory somatic (VEXAS) syndrome, an adult-onset inflammatory disease with an overlap of hematologic manifestations. VEXAS syndrome is characterized by a high mortality rate and significant clinical heterogeneity. We sought to determine independent predictors of survival in VEXAS and to understand the mechanistic basis for these factors. We analyzed 83 patients with somatic pathogenic variants in UBA1 at p.Met41 (p.Met41Leu/Thr/Val), the start codon for translation of the cytoplasmic isoform of UBA1 (UBA1b). Patients with the p.Met41Val genotype were most likely to have an undifferentiated inflammatory syndrome. Multivariate analysis showed ear chondritis was associated with increased survival, whereas transfusion dependence and the p.Met41Val variant were independently associated with decreased survival. Using in vitro models and patient-derived cells, we demonstrate that p.Met41Val variant supports less UBA1b translation than either p.Met41Leu or p.Met41Thr, providing a molecular rationale for decreased survival. In addition, we show that these 3 canonical VEXAS variants produce more UBA1b than any of the 6 other possible single-nucleotide variants within this codon. Finally, we report a patient, clinically diagnosed with VEXAS syndrome, with 2 novel mutations in UBA1 occurring in cis on the same allele. One mutation (c.121 A>T; p.Met41Leu) caused severely reduced translation of UBA1b in a reporter assay, but coexpression with the second mutation (c.119 G>C; p.Gly40Ala) rescued UBA1b levels to those of canonical mutations. We conclude that regulation of residual UBA1b translation is fundamental to the pathogenesis of VEXAS syndrome and contributes to disease prognosis.

1.
Beck
DB
,
Ferrada
MA
,
Sikora
KA
, et al
.
Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease
.
N Engl J Med.
2020
;
383
(
27
):
2628
-
2638
.
2.
Georgin-Lavialle
S
,
Terrier
B
,
Guedon
AF
, et al;
French VEXAS group
;
GFEV, GFM, CEREMAIA, MINHEMON
.
Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients
.
Br J Dermatol.
2022
;
186
(
3
):
564
-
574
.
3.
Bourbon
E
,
Heiblig
M
,
Gerfaud Valentin
M
, et al
.
Therapeutic options in VEXAS syndrome: insights from a retrospective series
.
Blood.
2021
;
137
(
26
):
3682
-
3684
.
4.
Tsuchida
N
,
Kunishita
Y
,
Uchiyama
Y
, et al
.
Pathogenic UBA1 variants associated with VEXAS syndrome in Japanese patients with relapsing polychondritis
.
Ann Rheum Dis.
2021
;
80
(
8
):
1057
-
1061
.
5.
Diarra
A
,
Duployez
N
,
Fournier
E
, et al
.
Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience
.
Blood Adv.
2022
;
6
(
3
):
998
-
1003
.
6.
Greenberg
P
,
Cox
C
,
LeBeau
MM
, et al
.
International scoring system for evaluating prognosis in myelodysplastic syndromes
.
Blood.
1997
;
89
(
6
):
2079
-
2088
.
7.
McAdam
LP
,
O’Hanlan
MA
,
Bluestone
R
,
Pearson
CM
.
Relapsing polychondritis: prospective study of 23 patients and a review of the literature
.
Medicine (Baltimore)
.
1976
;
55
(
3
):
193
-
215
.
8.
Damiani
JM
,
Levine
HL
.
Relapsing polychondritis--report of ten cases
.
Laryngoscope.
1979
;
89
(
6 Pt 1
):
929
-
946
.
9.
Arber
DA
,
Orazi
A
,
Hasserjian
R
, et al
.
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
.
Blood.
2016
;
127
(
20
):
2391
-
2405
.
10.
Hong
M
,
He
G
.
The 2016 revision to the World Health Organization classification of myelodysplastic syndromes
.
J Transl Int Med.
2017
;
5
(
3
):
139
-
143
.
11.
Kearse
MG
,
Wilusz
JE
.
Non-AUG translation: a new start for protein synthesis in eukaryotes
.
Genes Dev.
2017
;
31
(
17
):
1717
-
1731
.
12.
Poulter
JA
,
Collins
JC
,
Cargo
C
, et al
.
Novel somatic mutations in UBA1 as a cause of VEXAS syndrome
.
Blood.
2021
;
137
(
26
):
3676
-
3681
.
13.
Obiorah
IE
,
Patel
BA
,
Groarke
EM
, et al
.
Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1
.
Blood Adv.
2021
;
5
(
16
):
3203
-
3215
.
14.
Gallì
A
,
Todisco
G
,
Catamo
E
, et al
.
Relationship between clone metrics and clinical outcome in clonal cytopenia
.
Blood.
2021
;
138
(
11
):
965
-
976
.
15.
Li
M
,
Binder
M
,
Lasho
T
, et al
.
Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients
.
Blood Adv.
2021
;
5
(
8
):
2272
-
2278
.
16.
Poulter
J
,
Morgan
A
,
Cargo
C
,
Savic
S
,
Savic
S
;
UKGCA/VEXAS Consortium
.
A high-throughput amplicon screen for somatic UBA1 variants in cytopenic and giant cell arteritis cohorts [published online ahead of print 2 April 2022]
.
J Clin Immunol.
2022
. doi:10.1007/s10875-022-01258-w.
17.
Malcovati
L
,
Stevenson
K
,
Papaemmanuil
E
, et al
.
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS
[published correction appears in Blood. 2021;137(21):3003].
Blood.
2020
;
136
(
2
):
157
-
170
.
18.
Montalban-Bravo
G
,
Kanagal-Shamanna
R
,
Benton
CB
, et al
.
Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes
.
Blood Adv.
2020
;
4
(
3
):
482
-
495
.
19.
Nazha
A
,
Narkhede
M
,
Radivoyevitch
T
, et al
.
Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes
.
Leukemia.
2016
;
30
(
11
):
2214
-
2220
.
20.
Arnaud
P
,
Milleron
O
,
Hanna
N
, et al
.
Clinical relevance of genotype-phenotype correlations beyond vascular events in a cohort study of 1500 Marfan syndrome patients with FBN1 pathogenic variants
.
Genet Med.
2021
;
23
(
7
):
1296
-
1304
.
21.
Lee
PY
,
Kellner
ES
,
Huang
Y
, et al
.
Genotype and functional correlates of disease phenotype in deficiency of adenosine deaminase 2 (DADA2)
.
J Allergy Clin Immunol.
2020
;
145
(
6
):
1664
-
1672.e10
.
22.
Oliveira
JP
,
Ferreira
S
.
Multiple phenotypic domains of Fabry disease and their relevance for establishing genotype- phenotype correlations
.
Appl Clin Genet.
2019
;
12
:
35
-
50
.
23.
Ingolia
NT
,
Lareau
LF
,
Weissman
JS
.
Ribosome profiling of mouse embryonic stem cells reveals the complexity and dynamics of mammalian proteomes
.
Cell.
2011
;
147
(
4
):
789
-
802
.
24.
Na
CH
,
Barbhuiya
MA
,
Kim
MS
, et al
.
Discovery of noncanonical translation initiation sites through mass spectrometric analysis of protein N termini
.
Genome Res.
2018
;
28
(
1
):
25
-
36
.
25.
Karczewski
KJ
,
Francioli
LC
,
Tiao
G
, et al;
Genome Aggregation Database Consortium
.
The mutational constraint spectrum quantified from variation in 141,456 humans
[published corrections appear in Nature. 2021;590(7846):E53 and 2021;597(7874): E3-E4].
Nature.
2020
;
581
(
7809
):
434
-
443
.
26.
Heiblig
M
,
Ferrada
MA
,
Koster
MJ
, et al
.
Ruxolitinib is more effective than other JAK Inhibitors to treat VEXAS Syndrome: a retrospective multi center study [published online ahead of print 24 May 2022]
.
Blood.
2022
. doi:10.1182/blood.2022016642.
27.
Comont
T
,
Heiblig
M
,
Rivière
E
, et al;
French VEXAS study group, Groupe Francophone des Myélodysplasies (GFM) and MedecineINterne, HEmato et ONco (MINHEMON) group
.
Azacitidine for patients with vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry
.
Br J Haematol.
2022
;
196
(
4
):
969
-
974
.
28.
Arlet
JB
,
Terrier
B
,
Kosmider
O
.
Mutant UBA1 and severe adult-onset autoinflammatory disease
.
N Engl J Med.
2021
;
384
(
22
):
2163
.
29.
Kirino
Y
,
Takase-Minegishi
K
,
Tsuchida
N
, et al
.
Tocilizumab in VEXAS relapsing polychondritis: a single-center pilot study in Japan
.
Ann Rheum Dis.
2021
;
80
(
11
):
1501
-
1502
.
30.
Beck
DB
,
Grayson
PC
,
Kastner
DL
.
Mutant UBA1 and severe adult-onset autoinflammatory disease [reply]
.
N Engl J Med.
2021
;
384
(
22
):
2164
-
2165
.
You do not currently have access to this content.

Sign in via your Institution